These data support a model whereby RASSF1A and the Hippo pathway maintain differentiation status in tumours and prevent formation of CSCs, explaining the association of RASSF1A loss with aggressive lung adenocarcinoma. The gene discussed is RASSF1; the disease is neoplasm.